Breakthrough Treatment for Advanced HER2+ Lung Cancer
New FDA-approved drug sevabertinib offers hope for adults with metastatic or inoperable HER2-positive lung cancer, offering improved outcomes.
Sevabertinib, a groundbreaking new treatment, has been approved by the MHRA to treat adults with HER2-positive lung cancer that has spread or cannot be removed by surgery. This significant development offers hope to patients diagnosed with this aggressive form of the disease.
HER2-positive lung cancer is a rare subtype that accounts for approximately 2-4% of all lung cancer cases. Historically, it has been associated with poorer prognosis and limited treatment options compared to other lung cancer types. The approval of sevabertinib marks a major milestone in the fight against this challenging disease.
{{IMAGE_PLACEHOLDER}} alt=Source: UK Government
